ArticleViruses2010
Antiviral therapy for hepatitis C virus: beyond the standard of care.
Article in Viruses, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Inhibitors for the hepatitis C virus RNA polymerase explored by SAR with advanced machine learning methods.Bioorganic & medicinal chemistry · 2013Article
- Intervention strategies for emerging viruses: use of antivirals.Current opinion in virology · 2013Review
- Artemisinin analogues as potent inhibitors of in vitro hepatitis C virus replication.PloS one · 2013Article
- Hepatitis C virus NS5B and host cyclophilin A share a common binding site on NS5A.The Journal of biological chemistry · 2012Article
- The burden of untreated hepatitis C virus infection: a US patients' perspective.Digestive diseases and sciences · 2012Article
- New developments in small molecular compounds for anti-hepatitis C virus (HCV) therapy.Journal of Zhejiang University. Science. B · 2012Review
- Discovery and development of telaprevir: an NS3-4A protease inhibitor for treating genotype 1 chronic hepatitis C virus.Nature biotechnology · 2011Article
- Comparative study of the genetic barriers and pathways towards resistance of selective inhibitors of hepatitis C virus replication.Antimicrobial agents and chemotherapy · 2011Article
- Inhibition of hepatitis C virus replication by semi-synthetic derivatives of glycopeptide antibiotics.The Journal of antimicrobial chemotherapy · 2011Article
- Preclinical characterization of naturally occurring polyketide cyclophilin inhibitors from the sanglifehrin family.Antimicrobial agents and chemotherapy · 2011Article
- Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatitis C virus (HCV) represents a major health burden, with an estimated 180 million chronically infected individuals worldwide. These patients are at increased risk of developing liver cirrhosis and hepatocellular carcinoma. Infection with HCV is the leading cause of liver transplantation in the Western world. Currently, the standard of care (SoC) consists of pegylated interferon alpha (pegIFN-α) and ribavirin (RBV). However this therapy has a limited efficacy and is associated with serious side effects. Therefore more tolerable, highly potent inhibitors of HCV replication are urgently needed. Both Specifically Targeted Antiviral Therapy for HCV (STAT-C) and inhibitors that are believed to interfere with the host-viral interaction are discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.